In honor of the JPM Healthcare conference live in SF this week: how did health-related startups on Carta fare in 2022?
Amidst the general gloom - not too shabby.
When comparing 2022 to 2021, median pre-money valuations rose at the seed stage across healthtech, biotech, and medical devices. Of course the aperture matters greatly here (valuations in the second half of 2022 were lower than those in H1).
Once those seedlings grow into Series C companies, however, the picture lost some luster. Biotech and medical device valuations in particular suffered steep declines from 2021 peaks.
Health-related startups did not escape the general downturn in valuations, but were on the whole less affected than some other industries like fintech and consumer.
Enjoy the conference, here's to more healthtech in 2023 🏥
DISCLOSURE: This communication is on behalf of eShares, Inc. dba Carta, Inc. ("Carta"). This communication is for informational purposes only, and contains general information only. Carta is not, by means of this communication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services nor should it be used as a basis for any decision or action that may affect your business or interests. Before making any decision or taking any action that may affect your business or interests, you should consult a qualified professional advisor. This communication is not intended as a recommendation, offer or solicitation for the purchase or sale of any security. Carta does not assume any liability for reliance on the information provided herein. © 2026 Carta. All rights reserved. Reproduction prohibited.
